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In the present work, analytical methods, UV Spectrophotometry and Liquid Chromatography (HPLC), were developed and 
validated for quantification of cefpirome, a broad-spectrum fourth-generation cephalosporin, in raw material and powder for 
injectable preparation. The UV spectrophotometric method was performed at 271 nm, using 0.1 M hydrochloric acid as solvent. 
The HPLC was carried out using Techsphere ODS column and mobile phase consisted of methanol-water (30:70, v/v) with flow 
rate 0.8 mL/min and UV detection at 265 nm. The validation method yielded good results demonstrated statistically that the 
methods were linear, precise, accurate, specific and robust. A preliminary stability study of cefpirome showed that the UV 
Spectrophotometry and Liquid Chromatography methods were specific for the determination cefpirome in the presence of its 
degradation products. No statistically difference was observed between the proposed methods. The UV Spectrophotometry and 
Liquid Chromatography methods allow the quantitation of cefpirome in pharmaceutical dosage form and raw material and can be 
used for the drug analysis in routine quality control. 
 
Keywords: cefpirome, UV spectrophotometry, liquid chromatography, method validation, stability 
 
 
Introduction  
 
Cephalosporin is a group of broad-spectrum derived from 
species of fungi of the genus Cephalosporium and are 
related to the penicillins in both structure and mode of action 
but relatively penicillinase-resistant antibiotics. These 
antibiotics have low toxicity for the host, considering their 
broad antibacterial spectrum. They have the active nucleus 
of beta-lactam ring which results in a variety of antibacterial 
and pharmacologic characteristics when modified mainly by 
substitution at 3 and 7 positions. Their antibacterial 
activities result from the inhibition of mucopeptide synthesis 
in the cell wall. Traditionally, the cephalosporins are divided 
into first-, second-, third-, fourth and fifth-generation agents 
(1-3). 
Cefpirome, [6R-[6α,7β(Z)]]-1-[[(2-Amino-4-thiazolyl) 
(methoxyimino)acetyl] amino]-2-carboxy-8-oxo-5-thia-1-
azabicyclo[4.2.0]oct-2-em-3-yl]methyl]-6,7-dihydro-5H-
cyclopenta[b]pyrindinium inner salt (3) (Figure 1), is an 
injectable broad-spectrum aminothiazolyl cephalosporin, 
produced as sulfate salt. It is considered to be highly active 
against both gram-negative organisms including 
Pseudomonas aeruginosa and gram-positive organisms 
including staphylococci. It is stable to both plasmid and 
chromosomal β- lactamases and has been shown to induce 
less class I β- lactamase resistance than other cephalosporins 
(2,5-7). 
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Figure 1. Chemical structure of cefpirome  
 
The increased spectrum of activity, together with high 
stability against -lactamases and rapid transmembrane 
transport, distinguishes cefpirome as an example of a fourth-
generation cephalosporin and its principal use is in treatment 
for patients’ septic shock or several sepsis (2,5-10).  
Methods have been reported for the determination of 
cefpirome in plasma, serum, urine, tissue, raw material and 
pharmaceutical form. These methods include 
microbiological assay, HPLC, voltammetry assay, UV 
spectrometry and pH potentiometry (2,7-19). The aim of this 
study was to develop and validate simple and rapid UV 
Spectrophotometry and Liquid Chromatography (HPLC) 
methods for the quantification of cefpirome in raw material 
and powder for injectable preparation. These methods were 
validated according to the International Conference on 
Harmonization (ICH) guidelines (20). 
 
Materials and Methods 
 
Chemicals and reagents 
 
The cefpirome standard (assigned with content of cefpirome 
823 mg/g, batch n°. C 150.05 (SS)) was kindly supplied by 
Aventis Pharma (Frankfurt, Germany), pharmaceuticals 
dosage form (Cefrom® - injectable) containing cefpirome 
was obtained commercially from Aventis Pharma (São 
Paulo, Brazil) and it was claimed to contain 1 g (as 
anhydrous base). All reagents used were of analytical or 
HPLC grade, purchased from Tedia (Rio de Janeiro, Brazil), 
Lichrosolv (Darmstadt, Germany) and Merck (Darmstadt, 
Germany) and the water was ultra-purified by Filtrosul 
system (Porto Alegre, Brazil). 
 
UV spectrophotometric conditions 
The UV method and spectra were performed on a 
Schimadzu UV-visible spectrophotometer UV-1601 PC with 
Uvpc software (Shimadzu, Kyoto, Japan) using 1.0 cm 
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quartz cells, optical path of 10 mm. The spectra were 
recorded using 1 mm slit and 120 nm.min-1 scanning speed. 
The assay was performed at analytical wavelength 271 nm 
(with ± 0.5 nm of wavelength accuracy) and 0.1 M 
hydrochloric acid (HCl) as solvent. 
 
HPLC conditions 
The Liquid chromatography system consisted of a 
Schimadzu SCL-10A, with SPD-M10A Diode Array 
Detector (set at 265 nm), a SCL-10A VP system controller, 
a LC 10 AD VP pump, a SIL-10AD auto injector syringe 
unit, a CTO-10AC VP Column Oven (set at 25 °C), Class-
VP software (Shimadzu, Kyoto, Japan) and Techsphere® 
ODS RP-18 column (5 µm, 250 mm x 4.6 mm) (HPLC 
Technology - Welwyn Garden City, United Kingdom) fed 
with methanol-water (30:70, v/v) with flow rate 0.8 mL/min. 
 
Reference and samples preparation 
To UV spectrophotometry method, the reference and 
samples solutions were prepared using an amount of powder 
equivalent to 24 mg of cefpirome that was transferred to 100 
mL volumetric flask with 0.1 M hydrochloric acid and 
followed by making up to final volume with this solvent 
(240 µg/mL). An aliquot of this solution (5 mL) was 
transferred to the 100 mL volumetric flask and made up to 
final volume with 0.1 M hydrochloric acid (12 µg/mL). 
To HPLC method, the reference and samples solutions were 
prepared using an amount of powder equivalent to 25 mg of 
cefpirome that was transferred to 100 mL volumetric flask 
with ultra-purified water and followed by making up to final 
volume with this solvent (250 µg/mL). An aliquot of this 
solution (4 mL) was transferred to the 100 mL volumetric 
flask and made up to final volume with ultra-purified water 
(10 µg/mL). In each assay, 20 µL of solution was used. 
 
Methods validation 
The methods were performed and validated by 
determination of the following operational characteristics: 
linearity, range, precision, accuracy, specificity, limit of 
detection, limit of quantitation and robustness. 
 
Linearity 
The linearity of the methods were determined using 
cefpirome standard at different concentrations levels. Three 
calibration curves were prepared by day, for three 
consecutives days. The slopes and the statistical analysis of 
the calibration curves were calculated by linear regression. 
To UV spectrophotometry method, after choose the best 
solvent and wavelength, Ringbom’s curve was prepared 
using range concentration of cefpirome between 2.0 to 40.0 
µg/mL, using 0.1 M hydrochloric acid as solvent, the 
calibration curves were obtained after an amount of powder 
equivalent to 20 mg of cefpirome has transferred to 500 mL 
volumetric flask with 0.1 M hydrochloric acid, followed by 
making up to final volume with this solvent (40 µg/mL). 
Aliquots of this solution were transferred to the 20 mL 
volumetric flask and made up to final volume with 0.1 M 
hydrochloric acid to obtain the concentrations of 6.0, 8.0, 
12.0, 14.0 16.0, 18.0 and 22.0 µg/mL. Each solution was 
assayed three times. 
The calibration curves, to HPLC method, were prepared 
using range concentration of cefpirome between 2.0 to 20 
µg/mL. An amount of powder equivalent to 20 mg of 
cefpirome has transferred to 500 mL volumetric flask with 
ultra-purified water, followed by making up to final volume 
with this solvent (40 µg/mL). Aliquots of this solution were 
transferred to the 20 mL volumetric flask and made up to 
final volume with ultra-purified water to obtain the 
concentrations of 2.0, 5.0, 7.0, 10.0, 12.0 15.0, 18.0 and 20.0 
µg/mL. Triplicate injections of each solution were made into 
the HPLC system. 
 
Precision 
The precision of the assay was determined by repeatability 
(intra-assay) and intermediate precision (inter-assay). 
Repeatability was evaluated by assaying three samples at the 
same concentration and during the same day. The 
intermediate precision was certificated by comparing the 
assays on three different days. The precision is calculated by 
relative standard deviation (RSD) (20-22). 
 
Accuracy  
The accuracy was determined by recovery, in which known 
amount of cefpirome reference substance was added to the 
samples at the beginning of the process. The recovery test 
was performed at three concentration levels. The percentage 
recovery of cefpirome reference added was calculated using 
the equation proposed by AOAC (22). 
In UV spectrophotometry method, an amount of powder 
equivalent to 24 mg of cefpirome (sample) was transferred 
to 100 mL volumetric flask with 0.1 M hydrochloric acid 
and followed by making up to final volume with this solvent 
(240 µg/mL). An aliquot of this solution (5 mL) was 
transferred to the three 100 mL volumetric flask and aliquots 
of 5.0 mL, 10.0 and 15.0 mL of a 60 µg/mL of cefpirome 
reference substance were added in each volumetric flask and 
made up to final volume with 0.1 M hydrochloric acid 
(corresponding to 300, 600 and 900 µg, respectively). The 
solutions contending final concentrations of 15.0, 18.0 and 
21.0 µg/mL of cefpirome were submitted to the UV 
spectrophotometric assay described above. Each solution 
was prepared in triplicate in two days. 
To the HPLC method, an amount of powder equivalent to 25 
mg of cefpirome was transferred to 100 mL volumetric flask 
with ultra-purified water and followed by making up to final 
volume with this solvent (250 µg/mL). An aliquot of this 
solution (4 mL) was transferred to the three 100 mL 
volumetric flasks and aliquots of 5.0 mL, 7.5 and 10.0 mL 
of a 100 µg/mL of cefpirome reference substance were 
added in each volumetric flask and made up to final volume 
with ultra-purified water (corresponding to 0.5, 0.75 and 1.0 
mg, respectively) and made up to final volume with ultra-
purified water. The solutions contending final 
concentrations of 15.0, 17.5 and 20.0 µg/mL of cefpirome 
were submitted to the chromatographic assay described 
above. Each solution was prepared in triplicate and injected 
three times in two days. 
 
Specificity 
The specificity was determined by measurement in presence 
of degradation products. Commercially obtained samples 
were diluted in injectable water at a concentration of 100 
mg/mL of cefpirome were submitted to accelerated 
degradation at 40 °C for twenty four hours, in climatic 
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chamber with controlled humidity Nova Ética 420 LDC 
(Nova Ética, São Paulo, Brazil), for thermal stress, and 
solutions contending 0.6 mg/mL of cefpirome, for 
photodegradation studies using UV light (254 nm) for one 
hour, respectively. These solutions were then diluted with 
0.1 M hydrochloric acid to obtain the theoretical 
concentration of 12 µg/mL for UV spectrophotometry 
method, and with ultra purifies water to obtain the 
theoretical concentration of 10 µg/mL, for HPLC method, 
and were assayed against freshly prepared solution of 
reference standard and sample at the same concentrations. 
Each sample was analyzed six times. In the case of UV 
spectrophotometry method, was verificated the influence of 
others cephalosporins. In the case of the HPLC method, also 
was determined the peak purity. 
 
Detection limit 
The detection limit was calculated based on the standard 
deviation of the response and the slope. Both estimated from 
the calibration curve of the cefpirome (20). 
 
Quantitation limit 
The quantitation limit was calculated based on the standard 
deviation of the response and the slope. Both estimated from 
the calibration curve of the cefpirome (20). 
 
Robustness 
The evaluation of robustness was during the development 
phase and under study. In the case of UV spectrophotometry 
method, were studied the influence of concentration of 
solvent (0.08 and 0.12 M hydrochloric acids) and different 
equipment. In the case of HPLC method, were studied the 
influence of variations in mobile phase composition 
(methanol-water 35:65, 25:75 and 20:80 v/v), different 
solvent, different flow rate (0.7, 1.0 and 1.2 mL/min, 
different column and different equipment. 
 
Analytical solution stability 
The analytical solutions stability was determined by 
comparison of quantitation of components in solutions after 
storage conditions (depends on need) to freshly prepared 
standards. In this study, the solutions were kept at room 
temperature for 6 and 24 hours and stored refrigerated at 5 
°C for 24 and 48 hours. 
 
Results and Discussion 
 
The validation of analytical procedures is an important part 
of the registration application for a new pharmaceutical 
preparation. Beyond the regulatory requirements, the 
performance and reliability of the control test procedure are 
essential to the quality control of drugs. Results which 
reflect the quality of the pharmaceutical to be tested may 
easily lead to drastic financial consequences. Therefore, 
validation should be regarded as part of an integrated 
concept to ensure the quality, safety and efficacy of 
pharmaceuticals (23,24). 
The elaboration of the methods described was begun by 
developing optimal conditions. Several conditions were 
investigated for each method and chosen optimal variants 
against common criteria critical in quantitative analysis, 
such as solvent, selectivity and linearity. 
To choose the best wavelength and solvent to be used in UV 
spectrophotometry method, spectra were performed on UV-
VIS spectrophotometer using ultra purified water, 0.1 M 
hydrochloric acid, ethanol and methanol. 0.1 M hydrochloric 
acid and the wavelength 271 nm were chosen the best 
experimental conditions (Figure 2).  
 
 
Figure 2. Absorption spectrum of cefpirome in different solvents 
(12 µg/mL): (A) 0.1 M hydrochloric acid, (B) water; (C) methanol 
and (D) ethanol. 
 
The linearity of an analytical method is its ability to elicit 
test results that are directly, or by a well-defined 
mathematical transformation, proportional to the 
concentration of analyte in samples within a given range 
(25). 
Using the Ringbom’s curve (Figure 3), the calibration 
curves were performed and the results showed good linearity 
on the range of concentration of cefpirome between 2.0 to 
22.0 µg/mL for the UV spectrophotometry method (Figure 
4). The calibration curves were constructed by plotting 
concentration versus absorbance and showed good linearity 
with excellent correlation coefficients (r). The representative 
linear equation for cefpirome was y = 0.0437x + 0.0027 (n = 
9, r = 0.9994). There are no deviation from parallelism and 
linearity with results obtained (Fcalculated<Fcritical p = 
0.01) as showed in Table 1.  
 
 
Figure 3. Ringbom plot. Standard curve for cefpirome (2.0 – 40.0 
µg/mL, in 0.1 M hydrochloric acid), by UV spectrophotometry at 
271 nm. 
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Figure 4. Calibration curve of cefpirome in 0.1 M hydrochloric 
acid, by UV spectrophotometry at 271 nm. The best fit line 
calculated by the method of least squares is shown. 
 
Table 1. Analysis of variance of the data obtained from the UV 
Spectrophotometry method for determination of cefpirome. 
Source of 
variation 
Degrees of 
freedom 
Sum of 
Squares 
Mean 
squares 
F 
Between 6 2.169 0.361 4.41x105 1 
Regression 1 2.169 2.169 2.65x106 1 
Deviation 5 1.08x10-5 2.16x10-6 2.64 
Within 35 2.87x10-5 8.19x10-7 ----- 
Total 41 2.169 ----- ----- 
1Significant at p = 0.01 
Each value is the mean of 6 assays. 
 
For the development and validation of the method by HPLC, 
columns, solvents, different combinations and proportions of 
solvent, wavelength, flow, pH and temperatures were tested 
in order to obtain the best analytical conditions for 
quantification of cefpirome. The best system suitability was 
obtained when the Techsphere® ODS RP-18 column (5 µm, 
250 mm x 4.6 mm), methanol-water (30:70, v/v) as mobile 
phase, flow rate at 0.8 mL/min and temperature at 25 °C 
were used. The retention time of cefpirome was about 6.9 
min. as shown in Figure 5. 
 
In this HPLC method, the calibration curves were 
constructed by plotting concentration versus peak area and 
showed good linearity, on the range concentration of 
cefpirome between 2.0 to 20.0 µg/mL (Figure 6), with 
excellent correlation coefficients (r). The representative 
linear equation for cefpirome was y = 4.6823x + 0.4555 (n = 
6, r = 0.9996) There are no deviation from parallelism and 
linearity with results obtained (Fcalculated<Fcritical p = 
0.01) as showed in Table 2.  
 
The detection limit (DL) is the lowest amount of analyte in a 
sample that can be detected, but not necessarily quantitated, 
under the stated experimental conditions. The quantitation 
limit (QL) is the lowest amount of analyte in a sample that 
can be determined with acceptable precision and accuracy 
under stated experimental conditions. The DL and QL are 
usually expressed as the concentration of analyte in the 
sample (19-22). Although some guidelines of validation on 
analytical procedures don’t ask the calculation of DL and 
QL for the pharmaceutical product, these limits were 
determined in this study. In the case of the UV 
spectrophotometry method, the DL and QL were 0.19 and 
0.62 µg/mL, respectably. In the case of HPLC method, the 
DL and QL were 0.09 and 0.27 µg/mL respectably. These 
results showed that the both methods were very sensible. 
 
Figure 5. Chromatogram of cefpirome in ultra-purified water (12 
µg/mL): (A) cefpirome standard, (B) cefpirome sample. 
Chromatographic conditions: Techsphere® ODS RP-18 column (5 
µm, 250 mm x 4.6 mm), methanol-water (30:70, v/v) as mobile 
phase, flow rate at 0.8 mL/min and temperature at 25 °C. 
 
 
Figure 6. Calibration curve of cefpirome in water, by HPLC 
method at 265 nm. The best fit line calculated by the method of 
least squares is shown. 
 
Table 2. Analysis of variance of the data obtained from the HPLC 
method for determination of cefpirome. 
Source of 
variation 
Degrees 
of 
freedom 
Sum of 
Squares 
Mean 
squares 
F 
Between 7 36949.38 5278.48 6610.28 1 
Regression 1 36947.19 36947.19 46269.23 1 
Deviation 6 2.19 0.37 0.46 
Within 40 31.94 0.80 ----- 
Total 47 36981.32 ----- ----- 
1 Significant at p = 0.01 
Each value is the mean of 6 assays. 
y = 0.0437x + 0.0027 
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The precision of the assay was determined by repeatability 
and intermediate precision which results were expressed as 
the relative standard deviation (RSD) of a series of 
measurements in the same day and on different days 
respectively. The precision of an analytical method is the 
degree of agreement among individual test results when the 
method is applied repeatedly to multiple samplings of a 
homogeneous sample (20-23). The repeatability was studied 
by determination of the samples in six assays, at the same 
concentration, during the same day under the same 
experimental conditions. The result obtained shows RSD of 
0.47 and 0.99 to UV spectrophotometry and HPLC method, 
respectively, indicating good intra-assay precision. Inter-
assay variability was calculated from assays on 3 days and 
shows RSD of 0.80 and 1.24 to UV spectrophotometry and 
HPLC method, respectively (Tables 3 and 4).  
 
Table 3. Results of the determination of cefpirome in powder for injection by UV Spectrophotometry method. 
Sample 
(mg) 
Experimental amount1 
(mg) 
Concentration 
(mg/g)1 
Mean of concentration 
(mg/g) 
RSD (%)2 
Intra-assay 
RSD (%)2 
Inter-assay 
31.20 22.56 723.00    
31.30 22.78 727.70    
31.20 22.74 728.70 730.00 0.61  
31.20 22.85 732.30    
31.20 22.94 735.40    
31.20 22.86 732.70    
31.30 22.93 732.60    
31.20 22.54 722.50    
31.20 22.46 719.80 723.00 0.71  
31.30 22.47 718.00   0.80 
31.20 22.50 721.20    
31.20 22.58 723.80    
31.30 22.49 718.60    
31.20 22.37 716.90    
31.20 22.40 717.80 720.70 0.47  
31.30 22.61 722.20    
31.20 22.62 725.00    
31.30 22.65 723.60    
 Mean of concentration 724.60   
1 Mean of three determinations 
2 RSD (Relative standard deviation) 
 
Table 4. Results of the determination of cefpirome in powder for injection by HPLC method. 
Sample powder for 
injectable  
(mg) 
Experimental amount1 
(mg) 
Concentration 
(mg/g)1 
Mean of concentration 
(mg/g) 
RSD (%)2 
Intra-assay 
RSD (%)2 
Inter-assay 
40.00 28.62 715.53    
40.10 28.26 704.82    
40.20 28.34 704.96 712.48 1.04  
40.20 28.50 708.96    
40.10 28.78 717.67    
40.10 28.99 722.92    
40.00 28.43 710.83    
40.10 29.30 730.73    
40.50 29.54 729.41 724.64 0.99  
40.50 29.35 724.63   1.24 
40.10 29.07 724.91    
40.40 29.38 727.30    
39.90 28.27 708.41    
40.10 28.90 720.63    
40.20 29.17 725.73 718.11 1.21  
40.10 28.33 706.54    
40.40 29.37 726.90    
40.00 28.82 720.45    
 Mean of      concentration 718.41   
1 Mean of four determinations 
2 RSD (Relative standard deviation) 
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The accuracy was proved by recovery test that are 
experimental designs to determine the agreement between 
the values found of the analyte and the real value that 
analyses (20-23). The recovery test was performed with 
three different concentration was the mean recovery were 
found to be 98.41% of reference substance (UV 
spectrophotometry method) and 101.14% (HPLC method) 
(Tables 5 and 6). 
 
Table 5. Experimental values obtained in the recovery test for 
cefpirome in powder for injection by UV spectrophotometry 
method. 
Amount of 
standard added 
(µg) 
Amount of 
standard found 
(µg) 
Percentage recovery1 ± 
RSD(%)2 
300.0 290.7 97.98 ± 0.82 
600.0 589.5 99.34 ± 0.67 
900.0 871.6 97.92 ± 0.65 
1 Mean of six determinations. 
2 RSD (Relative standard deviation) 
 
 
Table 6. Experimental values obtained in the recovery test for 
cefpirome in powder for injection by HPLC method. 
Amount of 
standard added 
(µg) 
Amount of 
standard found 
(µg) 
Percentage recovery1 ± 
RSD(%) 
500.0 503.2 100.64± 0.94 
700.0 744.0 99.20 ± 0.89 
1000.0 1001.7 100.17 ± 0.73 
1 Mean of six determinations. 
2 RSD (Relative standard deviation) 
 
Specificity is defined as the ability to assess unequivocally 
the analyte in the presence of components that may be 
expected to be present, such as impurities, degradation 
products and matrix components (14-17). The specificity of 
the proposed methods was studied analysis of degraded 
samples (Figures 7 and 8). In case of the HPLC method, also 
was verificated the peak purity. The results obtained 
demonstrate that a decrease occurred in the concentration of 
cefpirome under the conditions used. The results were 
expressed as a percentage of the drug remaining (Tables 7 
and 8). 
 
Cefpirome was very instable at 40 °C and exposed to UV 
light (254 nm). After the degradation treatment, the contents 
of the containers were diluted with the 0.1 M hydrochloric 
acid or ultra-purified water, for UV spectrophotometry and 
HPLC methods, respectively, and showed loss of 
concentration (Figures 7 and 8).  
 
The spectrophotometric and chromatographic assays 
described were specific for the determination of cefpirome 
in the presence of possible degradation products. 
 
Figure 9 shows the purity curve obtained in the 
determination of cefpirome by the proposed 
chromatographic method in the analysis of the aqueous 
solution of the pharmaceutical form exposed to thermal 
degradation at 40 °C stored for two days. The high purity 
value indicates that the chromatographic method has 
specificity against the likely degradation products. 
 
 
Table 7. Results of Specificity and Robustness tests and analytical 
solution stability, by UV spectrophotometry assay. 
Sample 
Mean absorbance, 
RSD (%)1 
Mean 
concentration 
(%) 
Standard in 0.1 M HCl 0.570 (0.13) 100.00 
Sample in 0.1 M HCl 0.569 (0.67) 99.82 
Degradated sample stored 
at 40 °C for 2 days 
0.286 (0.74) 50.18 
Degradated sample (0.6 
mg/mL) stored at UV light 
(254 nm) for 1h  
0.278 (0.55) 48.72 
Standard solution stored at 
5 °C for 24h 
0.570 (0.39) 100.18 
Standard solution stored at 
5 °C for 48h 
0.569 (0.82) 99.74 
Sample solution stored at 
room temperature for 6h 
0.572 (0.91) 100.44 
Sample solution stored at 
room temperature for 24h 
0.567 (1.58) 99.57 
Sample in 0.8 M HCl 0.569 (1.02) 99.86 
Sample in 1.2 M HCl 0.567 (0.86) 99.51 
Equipment 2 2 0.565 (0.54) 99.19 3 
1 Mean of six determinations, RSD (Relative standard deviation). 
2 Equipment 2: Spectrophotometer SHIMADZU UV – 160A 
(Shimadzu, Kyoto, Japan). 
3 Statistic analyze by Student’s t-test demonstrated no significant 
difference between the two spectrophotometer (p =0.01). 
 
 
 
 
 
Figure 7. Absorption spectra of cefpirome in 0.1 M hydrochloric 
acid (12 µg/mL): (A) aqueous solution of cefpirome standard, 
degraded sample stored solution at 40 °C for 24h (B), degraded 
sample aqueous solution stored at UV light (254 nm) for 1h and 
(C) . 
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Table 8. Results of Specificity and Robustness tests and analytical 
solution stability, by HPLC method. 
Sample 
Mean Integrated 
peak area, RSD 
(%)1 
Mean 
concentration 
(%) 
Standard 468076.1 (0.23) 100.00 
Sample 469012,3 (0.21) 100.20 
Degradated sample stored 
at 40 °C for 2 days 
233804.0 (0.62) 49.95 
Degradated sample (0.6 
mg/mL) stored at UV light 
(254 nm) for 1h 
227531.8 (0.46) 48.61 
Standard solution stored at 
5 °C for 24h 
468450.6 (0.20) 100.08 
Standard solution stored at 
5 °C for 48h 
467888.9 (0.18) 99.96 
Sample solution stored at 
room temperature for 6h 
467701.6 (0.33) 99.92 
Sample solution stored at 
room temperature for 24h 
468450.6 (0.13) 100.08 
Flow rate 0.7 mL/min 467514.4 (0.18) 99.88 5 
Flow rate 1.0 mL/min 463816.6 (0.97) 99.09 5 
Flow rate 1.2 mL/min 466484.6 (0.66) 99.66 5 
Mobile phase methanol-
water (35:65 v/v) 
468403.7 (0.99) 100.07 5 
Mobile phase methanol-
water (25:75 v/v) 
467982.5 (0.78) 99.98 5 
Mobile phase methanol-
water (20:80 v/v) 
464003.8 (0.55) 99.13 5 
Equipment 2 2 468169.7 (0.33) 100.02 5 
Column 2 3 466812.3 (0.51) 99.73 5 
Solvent 2 4 467327.2 (0.22) 99.84 5 
1 Mean of six determinations, RSD (Relative standard deviation). 
2 Chromatographer Schimadzu LC-10A, with SPD-10A variable-
wavelength detector (set at 265 nm), an SCL-10A system 
controller, a LC 10 AS pump, a C-R6A integrator and Rheodyne 
injection valve with 20 µL loop (Shimadzu, Kyoto, Japan) 
3 ACE HPLC Column C18 (5 µ, 250 mm x 4 mm) (Nova 
Analitica, São Paulo, Brazil) 
4 Methanol Tedia (Tedia Brazil, Rio de Janeiro, Brazil) 
5 Statistic analyze by Student’s t-test demonstrated no significant 
difference between the two parameters (p = 0.01), 
 
 
Robustness is defined as a measure of capability of the 
method to remain unaffected by small, but deliberate 
variations in method parameters. The Tables 7 and 8 shows 
that the solutions assayed in robustness test exhibited no 
concentration changes of cefpirome. 
 
To generate reproducible and reliable results, the stability of 
sample solution, standards and reagents must be determined 
prior to initiating the method validation studies. It is often 
essential that solutions be stable enough to allow for delays. 
Samples and standards should be tested over a time period 
and quantitation of components should be determined by 
comparison to freshly prepared standards. A stability 
criterion for assay methods is that sample and standard 
solutions be stable for under defined storage conditions. 
Acceptable stability is 2% change in standard or sample 
response, relative to freshly prepared standards (23). 
 
 
Figure 8. Chromatogram of cefpirome in ultra-purified water (10 
µg/mL): (A) cefpirome reference substance, (B) cefpirome sample, 
(C) degraded sample solution stored at UV light (254 nm) for 1h 
and (D) degraded sample stored solution at 40 °C for 24h. 
 
 
 
Figure 9. Purity curve obtained by HPLC analysis of the aqueous 
solution of cefpirome (pharmaceutical form) exposed to thermal 
degradation at 40 °C for two days. 
 
The analytical solutions of cefpirome in 0.1 M hydrochloric 
acid (240 µg/mL) and water (reference - 250 µg/mL), kept at 
refrigerated temperature (5 °C) and room temperature for 24 
and 48 hours, exhibited no concentration changes of 
cefpirome changes (Tables 7 and 8). 
The methods were compared by Student’s t-test and no 
significant difference between UV spectrophotometry and 
HPLC was observed (p =0.01). 
The results obtained in these assays were very satisfactory. 
Performed validation proved that UV spectrophotometry and 
Liquid Chromatography are good methods for 
pharmaceutical analysis of cefpirome in raw material and 
powder for injection. 
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Conclusions 
 
The results indicated that the UV spectrophotometric and 
chromatographic assay hold linearity, precision, accuracy, 
specificity and robustness at concentration range from 6 to 
22 mg/mL, UV spectrophotometry method, and from 2 to 20 
mg/mL, HPLC method, being acceptable methods for the 
routine quality control of cefpirome in raw material and 
pharmaceutical preparation. 
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